Roche claims a first in breast can­cer as Tecen­triq/Abrax­ane com­bo nabs quick ap­proval in front­line use

In a key tri­umph for Roche’s run­ner-up check­point Tecen­triq, the FDA sanc­tioned a com­bo of the PD-L1 with Cel­gene’s Abrax­ane for front­line use in triple neg­a­tive breast can­cer.

The ac­cel­er­at­ed ap­proval marks the first can­cer im­munother­a­py reg­i­men ap­proved for this type of metasta­t­ic can­cer, the phar­ma gi­ant said, just months af­ter re­port­ing some his­toric Phase III da­ta on pro­gres­sion-free sur­vival.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER